Plasma Exchange Shows 90% Response Rate in Rare Myelin Antibody Disease Attacks
A meta-analysis of 475 attacks finds therapeutic plasma exchange delivers high response rates in MOGAD, a rare autoimmune brain disease.
Summary
A systematic review and meta-analysis examined therapeutic plasma exchange (TPE) as a treatment for attacks of MOG antibody-associated disease (MOGAD), a rare autoimmune condition affecting the central nervous system. Analyzing 49 studies covering 475 attacks, researchers found an overall response rate of 90%, though complete recovery occurred in only 30% of cases. Most patients also received corticosteroids alongside TPE. Brainstem syndrome responded slightly better, while cerebral syndrome showed poorer outcomes. The findings suggest TPE is a valuable add-on therapy for MOGAD attacks, but randomized controlled trials are still needed to firmly establish its efficacy and identify which patients benefit most.
Detailed Summary
MOG antibody-associated disease (MOGAD) is a rare autoimmune condition in which the immune system targets myelin oligodendrocyte glycoprotein, a protein on the surface of myelin-producing cells in the brain and spinal cord. Attacks can cause optic neuritis, myelitis, and brainstem or cerebral syndromes, often leading to significant disability if not treated effectively. Standard treatment relies on high-dose corticosteroids, but outcomes remain variable, prompting interest in therapeutic plasma exchange (TPE) as an adjunctive or rescue therapy.
This systematic review and meta-analysis pooled data from 49 observational studies reporting on 475 MOGAD attacks treated with TPE, drawn from PubMed, Embase, and Scopus through November 2024. The patient population was predominantly female (56%), with optic neuritis (60%) and myelitis (37.7%) as the most common presentations. TPE was combined with intravenous methylprednisolone in 93% of cases.
The pooled overall response rate — defined as complete or partial recovery — reached 90% (95% CI 82–94%), a notably high figure. However, complete recovery was achieved in only 30% of attacks (95% CI 22–40%), with substantial heterogeneity across studies. Meta-regression analysis found that brainstem syndrome was associated with slightly better outcomes, while cerebral syndrome predicted poorer recovery. Age, sex, and use as first-line therapy did not significantly predict complete recovery.
These results suggest TPE offers meaningful clinical benefit for MOGAD attacks, particularly when added to standard corticosteroid therapy. The high overall response rate is encouraging for clinicians managing acute attacks in this rare disease population.
Key caveats include the observational nature of all included studies, high heterogeneity in the complete recovery estimate, and the absence of randomized controlled trial data. Publication bias and variable follow-up durations may also influence the pooled estimates.
Key Findings
- Overall response rate (complete or partial recovery) to TPE in MOGAD attacks was 90%.
- Complete recovery was achieved in only 30% of attacks, with high heterogeneity across studies.
- 93% of patients received TPE combined with intravenous methylprednisolone.
- Brainstem syndrome predicted slightly better TPE response; cerebral syndrome predicted worse outcomes.
- Age, sex, and first-line vs. rescue TPE use did not significantly affect complete recovery rates.
Methodology
Systematic review and meta-analysis of 49 observational studies (475 attacks) identified through PubMed, Embase, and Scopus up to November 2024. Primary outcome was recovery classification (complete, partial, or none) at last follow-up. Meta-regression on aggregated data explored predictors of treatment response.
Study Limitations
All included studies are observational, limiting causal inference and introducing potential confounding. High statistical heterogeneity (I²=74%) in the complete recovery estimate reduces precision. Publication bias and variable follow-up durations may inflate reported response rates.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.